Cesca Therapeutics Inc. (NASDAQ:KOOL) Issues Favorable 40-Month Follow-Up Results Of SurgWerks Feasibility Study

Cesca Therapeutics Inc. (NASDAQ:KOOL) has disclosed on Wednesday 40-month follow-up results of its feasibility study evaluating SurgWerks for the treatment of late-stage, no-option critical limb ischemia (CLI), which was conducted at Fortis Escorts Heart Institute, New Delhi, India in 2011. Feasibility Study Design and Results The feasibility study enrolled 17 subjects with late-stage CLI who […]

Trending Stocks: Dynavax Technologies Corporation (NASDAQ:DVAX), Cesca Therapeutics Inc. (NASDAQ:KOOL), F5 Networks (NASDAQ:FFIV)

Boston, MA 10/14/2014 (wallstreetpr) – Dynavax Technologies Corporation (NASDAQ:DVAX) announced on 13th October that it had initiated phase 1/2 clinical trials of its drug candidate SD-101. The target drug is expected to treat “lymphoma.” The drug would be tested across multiple study centres and will be introduced into the patient intratumorally. The treatment would be […]